Reuters logo
BRIEF-Ionis Pharmaceuticals presents ‍new data at peripheral nerve society meeting to support potential benefit of Inotersen​
2017年7月10日 / 上午11点27分 / 4 个月前

BRIEF-Ionis Pharmaceuticals presents ‍new data at peripheral nerve society meeting to support potential benefit of Inotersen​

July 10 (Reuters) - Ionis Pharmaceuticals Inc

* Data presented at peripheral nerve society meeting further support potential benefit of Inotersen​

* ‍Phase 3 neuro-TTR study met both its primary endpoints, Norfolk QOL-DN and MNIS+7, with high statistical significance​

* Treatment with Inotersen resulted in statistically significant benefit in MNIS+7 versus placebo at 8 months of treatment, at 15 months of treatment​

* ‍Continuing to review full data package from neuro-TTR study, prepare regulatory marketing applications for submission this year​

* ‍Results continue to support favorable benefit-risk profile for Inotersen in patients with FAP​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below